Carba1
Based on 1 Customer Validation
Carba1 is a bifunctional Carbazole (HY-D0204) derivative that activates nicotinamide phosphoribosyltransferase (NAMPT) and enhances NAD biosynthesis. Carba1 binds to colchicine site of tubulin, enhancing the anti-tumor effect of various chemotherapy drugs, such as Paclitaxel (HY-B0015). Carba1 exerts neuroprotective effect and can regulate cell energy metabolism. Carba1 can be used for the researches of cancer and chemotherapy-induced peripheral neuropathy (CIPN).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.23%
- CAS No.: 2635394-10-2
- Formule: C18H15ClN2
- Masse moléculaire:294.78
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Glycolysis Compound Library
HY-L058
-
Cytoskeleton Compound Library
HY-L060
-
Neuroprotective Compound Library
HY-L070
-
Anti-Lung Cancer Compound Library
HY-L075
-
Metabolic Enzyme Compound Library
HY-L146
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Protein Kinase Compound Library
HY-L196
-
High-Throughput Bioactive Compound Library
HY-L205
Activité biologique
Carba1 (12 μM; 72 h) synergizes with Paclitaxel (HY-B0015), Docetaxel (HY-B0011), nab-Paclitaxel (HY-P99974), and Epothilone-B (HY-17029) to inhibit HeLa cell viability, reducing their GI50 values by 2.6, 3.8, 1.8 and 4.4 folds[1].
Carba1 (1-20 μM; 60 mins) enhances NAMPT activity in HeLa cells[1].
Carba1 (12 μM; 72 h) protects adult mouse DRG neurons from axonal degeneration induced by Paclitaxel, Cisplatin (HY-17394) and Bortezomib (HY-10227), reducing the degeneration index[1].
Carba1 (1-10 μM; 24 h) protects against Cisplatin-induced neurotoxicity and myelination impairment in rat DRG neurons[1].
Carba1 (12 μM, 2 h) regulates HeLa cell metabolism, increasing lactate, glutamate, ATP, and GTP levels, decreasing NAD+ levels, and enhancing glycolysis and glutaminolysis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Carba1 (60 mg/kg; i.v.; every 2 days for 10 days) does not promote tumor growth and does not inhibit the antitumor activity of Paclitaxel in tumor growth modeling[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Paclitaxel-induced rats neuropathy models[1]
-
Dosage:50 mg/kg
-
Administration:Intraperitoneally injection; on days 0, 1, 2, 4, 7, 9
-
Result:Prevented tactile allodynia.
Reduced serum neurofilament light chain (NfL) levels.
Maintained intraepidermal nerve fiber (IENF) density.
Chemical Information
-
CAS No. 2635394-10-2
-
Appearance Solid
-
Masse moléculaire 294.78
-
Formule C18H15ClN2
-
Color White to off-white
-
SMILES
CC1=CC(N2C=CC=C2)=C(C)C3=C1NC4=C3C=C(Cl)C=C4
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Pureté et documentation
-
Fiche technique (276 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Carba1 Related Classifications
HY-179523 Related Classifications
Powered by Bioz